Published in Cell Death Dis on October 02, 2014
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells. Front Oncol (2015) 1.05
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Oncotarget (2016) 0.79
NFATc2 is an intrinsic regulator of melanoma dedifferentiation. Oncogene (2015) 0.76
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov (2012) 3.88
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene (2010) 2.56
Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol (2005) 2.30
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther (2012) 2.21
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med (2013) 2.06
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest (2014) 1.81
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res (2012) 1.74
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res (2012) 1.70
Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene (2006) 1.69
Bcl-2 proteins and mitochondria--specificity in membrane targeting for death. Biochim Biophys Acta (2010) 1.66
BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene (2004) 1.58
BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol Cell (2013) 1.48
VENNTURE--a novel Venn diagram investigational tool for multiple pharmacological dataset analysis. PLoS One (2012) 1.36
Resistance to RAF inhibitors revisited. J Invest Dermatol (2013) 1.33
MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst (2013) 1.31
The N-terminal end of Bax contains a mitochondrial-targeting signal. J Biol Chem (2003) 1.29
Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis (2010) 1.25
Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal (2013) 1.19
Targeted therapy for melanoma: rational combinatorial approaches. Oncogene (2013) 1.18
Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene (2003) 1.16
Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene (2007) 1.15
Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences. Mol Ther (2010) 1.14
Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol (2001) 1.10
Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer Cell (2012) 1.05
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res (2012) 1.01
TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria. J Immunol (2000) 1.00
Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res (2006) 0.98
Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J Invest Dermatol (2010) 0.97
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis (2014) 0.96
NFATc2 is a potential therapeutic target in human melanoma. J Invest Dermatol (2012) 0.95
RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells. J Invest Dermatol (2013) 0.95
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res (2013) 0.95
Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. Int J Cancer (2013) 0.95
ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis. Cell Death Dis (2013) 0.93
Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1. Cancer Lett (2012) 0.91
The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. Blood (2011) 0.91
Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res (2012) 0.90
TRAIL negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions. Angiogenesis (2013) 0.81
On the TRAIL to overcome BRAF-inhibitor resistance. J Invest Dermatol (2014) 0.79